The ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy2j/dy2j mouse model of muscular dystrophy

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Nevo, Yoram ^a   Aga Mizrachi, Shlomit ^a   Elmakayes, Edva ^a   Yanay, Nurit ^a   Ettinger, Keren ^a   Elbaz, Moran ^a   Brunschwig, Zivia ^a   Dadush, Oshrat ^a   Elad Sfadia, Galit ^b   Haklai, Roni ^b   Kloog, Yoel ^b   Chapman, Joab ^b   Reif, Shimon ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SALIRASIB; DRUG DERIVATIVE; FARNESOL; PRIMER DNA; SALICYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GRIP STRENGTH; LEG MUSCLE; MALE; MOUSE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; MYOFIBROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUADRICEPS FEMORIS MUSCLE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FIBROSIS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; WESTERN BLOTTING;

ANIMALIA; MUS;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DNA PRIMERS; FARNESOL; FIBROSIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MUSCLE STRENGTH; MUSCULAR DYSTROPHIES; RAS PROTEINS; SALICYLIC ACIDS;

EID: 79952954167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018049     Document Type: Article

References (49)

1. Muntoni F, Voit T, (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 14: 635-649.
2. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F, (2005) Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 62: 809-823.
3. Xu H, Wu XR, Wewer UM, Engvall E, (1994) Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 8: 297-302.
4. Vilquin JT, Vignier N, Tremblay JP, Engvall E, Schwartz K, et al. (2000) Identification of homozygous and heterozygous dy2J mice by PCR. Neuromuscul Disord 10: 59-62.
5. Colognato H, Yurchenco PD, (1999) The laminin alpha2 expressed by dystrophic dy(2J) mice is defective in its ability to form polymers. Curr Biol 9: 1327-1330.
6. Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, et al. (2008) Animal models for genetic neuromuscular diseases. J Mol Neurosci 34: 241-248.
7. Shorer Z, Philpot J, Muntoni F, Sewry C, Dubowitz V, (1995) Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J Child Neurol 10: 472-475.
8. Miyagoe-Suzuki Y, Nakagawa M, Takeda S, (2000) Merosin and congenital muscular dystrophy. Microsc Res Tech 48: 181-191.
9. Schessl J, Zou Y, Bonnemann CG, (2006) Congenital muscular dystrophies and the extracellular matrix. Semin Pediatr Neurol 13: 80-89.
10. Bokoch GM, Der CJ, (1993) Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J 7: 750-759.
11. Reuther GW, Der CJ, (2000) The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 12: 157-165.
12. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, et al. (1997) The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277: 333-338.
13. Kafri M, Kloog Y, Korczyn AD, Ferdman-Aronovich R, Drory V, et al. (2005) Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 168: 46-55.
14. Clarke HC, Kocher HM, Khwaja A, Kloog Y, Cook HT, et al. (2003) Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol 14: 848-854.
15. Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, et al. (2001) Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol 126: 570-577.
16. Weijzen S, Velders MP, Kast WM, (1999) Modulation of the immune response and tumor growth by activated Ras. Leukemia 13: 502-513.
17. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, et al. (1998) Dislodgment and accelerated degradation of Ras. Biochemistry 37: 1306-1314.
18. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, et al. (1995) Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270: 22263-22270.
19. Kloog Y, Cox AD, (2000) RAS inhibitors: potential for cancer therapeutics. Mol Med Today 6: 398-402.
20. Le DT, Shannon KM, (2002) Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol 9: 308-315.
21. Egozi Y, Weisz B, Gana-Weisz M, Ben-Baruch G, Kloog Y, (1999) Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80: 911-918.
22. Reif S, Aeed H, Shilo Y, Reich R, Kloog Y, et al. (2004) Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 41: 235-241.
23. Reif S, Weis B, Aeed H, Gana-Weis M, Zaidel L, et al. (1999) The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol 31: 1053-1061.
24. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, et al. (1995) Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38: 1267-1272.
25. Dadush O, Aga-Mizrachi S, Ettinger K, Tabakman R, Elbaz M, et al. (2010) Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate. Neuromuscul Disord 20: 267-272.
26. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y, (2002) Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277: 37169-37175.
27. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP, (1988) Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 154: 832-838.
28. Lisi MT, Cohn RD, (2007) Congenital muscular dystrophies: new aspects of an expanding group of disorders. Biochim Biophys Acta 1772: 159-172.
29. Karnoub AE, Weinberg RA, (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531.
30. Downward J, (2006) Signal transduction. Prelude to an anniversary for the RAS oncogene. Science 314: 433-434.
31. Quilliam LA, Rebhun JF, Castro AF, (2002) A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 71: 391-444.
32. Blum R, Cox AD, Kloog Y, (2008) Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 3: 31-47.
33. Kloog Y, Cox AD, Sinensky M, (1999) Concepts in Ras-directed therapy. Expert Opin Investig Drugs 8: 2121-2140.
34. Guo LT, Zhang XU, Kuang W, Xu H, Liu LA, et al. (2003) Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 13: 207-215.
35. Elad G, Paz A, Haklai R, Marciano D, Cox A, et al. (1999) Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452: 228-242.
36. Carmeli E, Moas M, Reznick AZ, Coleman R, (2004) Matrix metalloproteinases and skeletal muscle: a brief review. Muscle Nerve 29: 191-197.
37. VanSaun MN, Matrisian LM, (2006) Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 78: 69-79.
38. Choi YC, Dalakas MC, (2000) Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54: 65-71.
39. Matrisian LM, (1992) The matrix-degrading metalloproteinases. Bioessays 14: 455-463.
40. Bani C, Lagrota-Candido J, Pinheiro DF, Leite PE, Salimena MC, et al. (2008) Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 37: 583-592.
41. Lattanzi G, Muntoni F, Sabatelli P, Squarzoni S, Maraldi NM, et al. (2000) Unusual laminin alpha2 processing in myoblasts from a patient with a novel variant of congenital muscular dystrophy. Biochem Biophys Res Commun 277: 639-642.
42. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, et al. (1999) Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 205: 158-170.
43. Schoser BG, Blottner D, Stuerenburg HJ, (2002) Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 105: 309-313.
44. Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A, (2009) Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 18: 2584-2598.
45. Fingleton B, (2007) Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13: 333-346.
46. Rubio N, Gonzalez-Tirante M, Arevalo MA, Aranguez I, (2008) Over-expression of GTP-binding proteins and GTPase activity in mouse astrocyte membranes in response to Theiler's murine encephalomyelitis virus infection. J Neurochem 104: 100-112.
47. Pahan K, Liu X, McKinney MJ, Wood C, Sheikh FG, et al. (2000) Expression of a dominant-negative mutant of p21(ras) inhibits induction of nitric oxide synthase and activation of nuclear factor-kappaB in primary astrocytes. J Neurochem 74: 2288-2295.
48. Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, et al. (2010) Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice. Muscle Nerve 42: 218-229.
49. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.